CanSino Biologics Inc. (688185.SS) SHH

Currency In CNY

Key Executives

Name	Title	Pay	Year Born
Xuefeng Yu	Co-Founder, Executive Chairman, Chief Executive Officer & GM	3.83M	1964
Shou-Bai Chao	Chief Operating Officer, Deputy GM & Executive Director	2.55M	1963
Jing Wang	Chief Commercial Officer, Deputy GM & Executive Director	3.35M	1981
Dongxu Qiu	Co-Founder, Executive Vice President & Deputy GM	3.74M	1960
Tao Zhu	Co-Founder, Deputy GM & Chief Scientific Officer	4.42M	1973
Bei Bei Gao	Accounting Supervisor	0	N/A
Ming Liu	Acting Head of Finance	0	N/A
Chunlin Xin	Senior Director of New Technology Department	0	N/A
Jin Cui	Board Secretary	0	1987
Ming King Chiu FCIS	Joint Company Secretary	0	1977
Yonghui Wu	Vice President of Marketing	0	N/A

Name

Title

Pay

Year Born

Xuefeng Yu

Co-Founder, Executive Chairman, Chief Executive Officer & GM

3.83M

1964

Shou-Bai Chao

Chief Operating Officer, Deputy GM & Executive Director

2.55M

1963

Jing Wang

Chief Commercial Officer, Deputy GM & Executive Director

3.35M

1981

Dongxu Qiu

Co-Founder, Executive Vice President & Deputy GM

3.74M

1960

Tao Zhu

Co-Founder, Deputy GM & Chief Scientific Officer

4.42M

1973

Bei Bei Gao

Accounting Supervisor

N/A

Ming Liu

Acting Head of Finance

N/A

Chunlin Xin

Senior Director of New Technology Department

N/A

Jin Cui

Board Secretary

1987

Ming King Chiu FCIS

Joint Company Secretary

1977

Yonghui Wu

Vice President of Marketing

N/A

Description

CanSino Biologics Inc. is a company dedicated to the development, manufacturing, and commercialization of vaccines across the People's Republic of China. Its current offerings encompass vaccines for recombinant novel coronavirus disease, specifically Convidecia and the Ad5-nCoV for inhalation, along with Ad5-EBOV, an Ebola virus vaccine. The company also provides MCV2 and MCV4, which are designed to prevent N. meningitides infections. CanSino's pipeline includes an infant DTcP vaccine and a DTcP Booster vaccine, both undergoing Phase I clinical trials, with the latter specifically aimed at enhancing protection against pertussis after primary immunization. A Tdcp vaccine for adolescents and adults, likewise focused on pertussis, is another product in development. Further candidates currently in Phase I trials are PBPV, a protein-based pneumococcal vaccine providing serotype-independent immunity; PCV13i, a pneumococcal conjugate vaccine; and a TB Booster intended for individuals previously vaccinated against tuberculosis with BCG. Beyond its clinical stage assets, the firm is also pursuing a variety of preclinical products. These encompass a DTcP-Hib Combo vaccine; CSB012, which targets adenovirus; CSB013 for the Zika virus; CSB015 for meningitis; CSB016 for shingles; and CSB107 for polio. Established in 2009, CanSino Biologics Inc. maintains its corporate headquarters in Tianjin, People's Republic of China.